|
|
Article: Assessment of Current and Future Opportunities and Threats in the Insomnia Market in the US, EU and Japanese Pharmaceutical Markets.
- Article from:
- Business Wire
- Article date:
- March 2, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c33616) has announced the addition of Pipeline and Commercial Perspectives: Insomnia to their offering
Until recently, the insomnia market has been dominated by Ambien, Sonata, and Imovane, and the older hypnotics such as benzodiazepines. However, the global insomnia market is set to grow from $3.7 billion in 2005 to $5.5 billion by 2014 (CAGR, 5.6% 200514), driven primarily by the launch and up-take of Lunesta, Rozerem and Ambien CR as well as pipeline drugs from 2006 onwards.
Scope of this title:
- Overview of current market including profiles of key brands and ...